Cullinan Oncology, in partnership with Taiho Pharmaceutical (TADAWUL:2070), a subsidiary of Otsuka Holdings Co (OTC:OTSKY). (4578-JP; not rated), is planning to engage in discussions with the FDA ...

ByInvesting.com • May 23, 2024 Cullinan Therapeutics Files for 14.42M Share Offering by Selling Stockholders Cullinan Therapeutics (CGEM) has filed for up to 14,421,070 share offering by selling ...

Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619 ...

Oncology The Company continues enrollment of disease-specific expansion cohorts of its Phase 1 study. Cullinan remains on track to report initial data for endometrial and cervical cancers in the ...

Cullinan Therapeutics ... The company is committed to advancing its pipeline in immunology and oncology, with multiple ongoing trials and an emphasis on impactful catalysts for 2025.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619 ...

Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA ...

This page features the latest news about the Cullinan Oncology LLC stock. Cullinan Therapeutics' chief medical officer sells $52,851 in stock CAMBRIDGE, MA—Jeffrey Alan Jones, the Chief Medical ...